Stock Analysis

NCR Atleos Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

NYSE:NATL
Source: Shutterstock

NCR Atleos (NYSE:NATL) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.08b (up 1.0% from 3Q 2023).
  • Net income: US$24.0m (up from US$58.0m loss in 3Q 2023).
  • Profit margin: 2.2% (up from net loss in 3Q 2023).
  • EPS: US$0.33 (up from US$0.82 loss in 3Q 2023).
earnings-and-revenue-growth
NYSE:NATL Earnings and Revenue Growth November 14th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

NCR Atleos Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Diversified Financial industry in the US.

Performance of the American Diversified Financial industry.

The company's shares are up 3.7% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for NCR Atleos (1 is significant!) that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if NCR Atleos might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.